Beijing Peking University Weiming Bioengineering Group Co., Ltd.

Beijing Peking University Weiming Bioengineering Group Co., Ltd. (abbreviated as: Weiming Group) is one of the three major industrial groups of Peking University. It is mainly engaged in the development of the biological industry and the establishment of a bioeconomy system, with key investments in six major fields: biopharmaceuticals, bioagriculture, bioenergy, bioenvironmental protection, bioservices, and biomanufacturing. The Group has developed into a flagship enterprise of China's modern biological industry and one of the Chinese enterprise groups with the greatest potential for international competitiveness.
Over the more than twenty years since its establishment, Weiming Group has adhered to the philosophy of "rejuvenating the nation through science and education, serving the country through industry, and strengthening the nation through health," and is committed to "building a bioeconomy system and creating a bioeconomy flagship." It has formed three major advantages: "a solid industrial foundation, an innovative economic model, and a unique development approach." It has carried out a large amount of pioneering and breakthrough work for the development of China's biological industry and achieved remarkable results, creating multiple "world firsts" and "China firsts" in the course of China's biological industry development: it successfully brought to market China's first genetically engineered drug with independent intellectual property rights—recombinant interferon α1b (Sai Ruo Jin)—and made "Sai Ruo Jin" the leading brand in China's interferon market; it successfully operated China's first modern biopharmaceutical enterprise—Shenzhen Kexing Company—creating a miracle in China's biological industry; Beijing Kexing Company successfully developed the world's first "SARS virus inactivated vaccine" and China's first "human avian influenza vaccine," successfully produced the world's first influenza A (H1N1) vaccine, and successfully developed the world's first hand, foot, and mouth disease vaccine, creating yet another miracle in China's biological industry; Xiamen Peking University Zhilu Company successfully developed and produced the world's first therapeutic drug for neurological trauma—"nerve growth factor"—which is also the first Nobel Prize achievement industrialized first by Chinese people; the third-generation hybrid breeding technology successfully developed by Weiming Kaituo Company will trigger a third agricultural revolution; the biological intelligence technology of Weiming Bosi Company (the core technology of fifth-generation computers) is at the leading level of the world's new-generation information technology; in particular, Weiming Group has initially established the world's first "bioeconomy incubator," founded bioeconomy theory, built a bioeconomy system, practiced the bioeconomy model, and developed the bioeconomy industry. Weiming Group has become the source of the world's bioeconomy.
Weiming Group is building and implementing a world-leading bioeconomy system comprising three major systems: research and development, industry, and finance. It strives to achieve the goals of creating a leading enterprise, cultivating an excellent team, and triggering an industrial revolution, to build Weiming Group into a flagship of the bioeconomy era and make its own contribution to China's sustainable development and the realization of the "Chinese Dream" of the great rejuvenation of the Chinese nation!